Nova Scotia Guidelines for Acute Coronary Syndromes (2008) QUICK REFERENCE MARCH Supported by unrestricted educational grants from:

Similar documents
Ischemic heart disease (angina/chest pain)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION

Acute Coronary Syndromes. Case 1. Management Aims in ACS. Acute Coronary Syndromes. Ranil de Silva

Significance of Chronic Kidney Disease in 2015

ST Elevated Myocardial Infarction- Latest AHA recommendations

* * FORM REV. 02/2019 Page 1 of 4. TNKASE (tenecteplase) / ACUTE STEMI ORDERS SCHEDULED MEDICATIONS:

Επείγοντα καρδιολογικά προβλήματα- Διαγνωστικές και θεραπευτικές προκλήσεις Οξεία περικαρδίτιδα

Acute Coronary Syndrome

ST Elevation Myocardial Infarction (STEMI) Reperfusion Order Set

EASTERN ARIZONA COLLEGE Advanced Cardiovascular Life Support

Acute Coronary Syndromes

Emergency Department Performance Measures

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Cambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions.

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Angina Luis Tulloch, MD 03/27/2012

EASTERN ARIZONA COLLEGE Advanced Cardiac Life Support Renewal

Υποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν.

Harold P. Adams, Jr., MD Department of Neurology Carver College of Medicine UIHC Comprehensive Stroke Center University of Iowa

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Annex III. Amendments to relevant sections of the Product Information

Chest Pain - Clinical Pathway: Emergency

Update on Antithrombotic Therapy in Acute Coronary Syndrome

Management of Acute Myocardial Infarction

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

Paediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Frequently Asked Questions: IS RT-Q-PCR Testing

Cardiac Rehabilitation Services

SURGICAL NOTE. Surgical Recommendations to Optimize Femoral/Iliac Artery Cannulation

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

WESTERN NEW YORK / ECMC - ADULT INDUCED HYPOTHERMIA STATUS POST CARDIAC ARREST ORDERS (PG 1 OF 5)

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Treatment of Acute Coronary Syndromes

Objectives. Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2

Obesity/Morbid Obesity/BMI

Acute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC

Scenario Development Template

Guidelines for the Admission of Children and Young People with an Eating Disorder

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

Eating Disorders. what do GPs need to know? John O Brien May 2016

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

US Public Health Service Clinical Practice Guidelines for PrEP

Low Molecular Weight Heparin Prescribing and Administration (Adults)

Acute Coronary Syndrome (ACS) Initial Evaluation and Management

DISCUSSION QUESTION - 1

Center for Circulatory Support. The Center for Circulatory Support strives for continuous improvement in quality and patient outcomes

Cardiology Cath Conference

3. After I.V. or S.C. administration, onset is rapid, usually within 30 seconds, with duration of 5 to 10 minutes.

Objectives. Treatment of ACS. Early Invasive Strategy. UA/NSTEMI General Concepts. UA/NSTEMI Initial Therapy/Antithrombotic

5.0: Rare Bleeding Disorders

Meeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C

2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092

2018 CMS Web Interface

PBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System

KP National Cardiovascular Risk and Dyslipidemia Management Guideline

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Eating Disorder Clinical Practice Guideline Algorithm

Do Not Cite. Draft for Work Group Review.

Solid Organ Transplant Benefits to Change for Texas Medicaid

APPENDIX A Certification of Advanced Disease:

Acute Coronary Syndrome

ACEM Fellowship Examination Emergency Medicine Practice Questions SAQ

Safety of HPV vaccination: A FIGO STATEMENT

Pain relief after surgery

Prostatitis - chronic - Management

Access to Heme Treatment in Canada - Survey 2018

2018 Acute Coronary Syndrome. Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute

PULMONARY EMBOLISM (PE), SUSPECTED ACUTE ALGORITHM

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

Clinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition

BP Thresholds for Medical Review

Individual Assessments for Couples Treatment with HFCA

ICD-10-CM Coding Basics Chapter Specifics

HYPERTENSION AN OVERVIEW. Compiled by. Campbell M Gold (2008) CMG Archives --()-- IMPORTANT

CLINICAL MEDICAL POLICY

Swindon Joint Strategic Needs Assessment Bulletin

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Hospital Preparedness Checklist

2010 ACLS Guidelines. Primary goals of therapy for patients

Package leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium

Essentials of Blood Pressure Management Session 5: Blood Pressure, Kidneys and Complications

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Clinical Practice Guideline for the Management of Obesity in Adults

4. Which survey program does your facility use to get your program designated by the state?

Transcription:

Nva Sctia Guidelines fr Acute Crnary Syndrmes (2008) QUICK REFERENCE MARCH 2010 Supprted by unrestricted educatinal grants frm:

Critical Pathways STEMI in the Emergency department EVALUATION Vital Signs 12-lead ECG (within 10 minutes f arrival), then q 30 minutes x 3 IV x 2 Inserted Trpnin immediately and q 8 hurs x 2 CBC PT/aPTT 0 2 t maintain sats >95% Chemistry Panel Chest Xray Mnitred Bed Estimate CrCl (<30 ml/min is equivalent t severe renal insufficiency) Ideal bdy weight (IBW) (kg) = 0.9 (Ht [cm] -150) (+50, male; + 45, female) CrCl frmula (ml/min): Male: (140 - age) (IBW kg) (60) (Serum creatinine uml/l) (50) Female: 0.85 x male CrCl value Determine Eligibility fr Reperfusin Review Cntraindicatins and Timelines Primary PCI (dr t balln <90 minutes) Thrmblysis (dr t needle <30 minutes) u See Over t

Medicatin fr STEMI Aspirin u 160-325 mg Clpidgrel u 300 mg p, (reduce dse t 75 mg if 75 and receiving TNK) Metprll u 5 mg IV q 5 min prn if HR >100 and SBP >110 and n heart failure Nitrates u 0.3-0.6 mg SL q 5 min x3 until pain free r SBP 100 Mrphine u 2-4 mg IV r subcut q 30 min prn pain Fentanyl u 50-100 mcg IV q 30 min prn pain Anticagulant (Chse ONE): Enxaparin u <75 years f age: administer a fixed 30 mg IV blus, fllwed by subcut injectin 1mg/kg (max 100mg/dse fr first 2 subcut injectins) twice daily (BID) u 75 years f age: Omit blus; reduce subcut injectin t 0.75 mg/kg BID (max 75 mg/dse fr first 2 subcut injectins) Unfractinated u IV lading dse f 60 IU/kg (max 4000 IU); subsequent Heparin (UFH) IV infusin f 12 IU/kg/hur (Max 1000 IU/hur). (use if CrCl adjust dse as per lcal nmgram. <30 ml/mins; r cncern re bleeding risk)

Abslute Cntraindicatins t Fibrinlysis Any prir intracranial hemrrhage (ICH) Knwn structural cerebral vascular lesin (ie., arterivenus malfrmatin) Knwn malignant intracranial neplasm (primary r metastatic) Ischemic strke within 3 mnths EXCEPT acute ischemic strke within 4 hurs Suspected artic dissectin Active bleeding r bleeding diathesis (excluding menses) Significant clsed-head r facial trauma within 3 mnths Adapted frm Antman EM, et al J Am Cll Cardil. 2004; 44:E1-E2111 u See Over t

Relative Cntraindicatins t Fibrinlysis Histry f chrnic, severe, prly cntrlled hypertensin Severe uncntrlled HTN n presentatin (SBP > 180 mm Hg r DBP >110 mm Hg) Histry f prir ischemic strke >3 mnths, dementia, r knwn intracranial pathlgy nt cvered in abslute cntraindicatins Traumatic r prlnged (>10 minutes) CPR r majr surgery (<3 weeks) Recent (within 2-4 weeks) internal bleeding Nncmpressible vascular punctures Fr streptkinase/anistreplase: prir expsure (>5 days ag) r prir allergic reactin t these agents Pregnancy Active peptic ulcer Current use f anticagulants: the higher the INR, the higher the risk f bleeding Adapted frm Antman EM, et al J Am Cll Cardil. 2004; 44:E1 - E2111

STEMI Wh shuld g fr cath? Risk Stratificatin and Triage fr Cardiac Catheterizatin Primary PCI Emergent Catheterizatin Lytic ineligible and < 12 hurs frm symptm nset Cardigenic shck Rescue PCI* Failure t reperfuse (<50% reslutin f ST elevatin @ 90 min) Recurrent ST elevatin fr 15-30 min after successful lysis** High risk/cmplicated STEMI Mechanical cmplicatins - VSD, papillary muscle rupture Recurrent/ refractry ischemia Recurrent ventricular arrhythmias Refractry bradycardia Severe heart failure r persistent hyptensin - VAD (ventricular assist device team) shuld be ntified * symptm nset t balln time is predicted t be < 12 hurs ** cnsider repeat lysis if rescue nt available within 60-90 min NON-Emergent Catheterizatin Patients with high risk STEMI (e.g. extensive MI invlving 2 territries [anterlateral, inferlateral, inferpsterir]) and wh have respnded well t the initial thrmblysis may be cnsidered fr cardiac catheterizatin during the current hspitalizatin withut underging nn-invasive risk stratificatin. Patients with lw risk STEMI (e.g. islated uncmplicated inferir infarctin) wh have respnded well t thrmblysis shuld underg a nninvasive risk stratificatin test, such as an exercise tlerance test, prir t discharge t determine the need fr cardiac catheterizatin. Cntact Telephne Numbers: Cath Lab @ QEII (day): (902) 473-6532 r (902) 473-6633 Evening: Page the n-call Interventinal Cardilgist: (902) 473-2222 Ventricular Assist Device Team: (902) 223-0715

Critical Pathways UA/NSTEMI in the Emergency department EVALUATION Vital Signs 12-lead ECG (within 10 minutes f arrival), then 1 hur x 3 IV x 2 Inserted Trpnin immediately and q 8 hurs x 2 CBC PT/aPTT 0 2 t maintain sats >95% Chemistry Panel Chest Xray Mnitred Bed Estimate CrCl (<30 ml/min is equivalent t severe renal insufficiency) Ideal bdy weight (IBW) (kg) = 0.9 (Ht [cm] -150) (+50, male; + 45, female) CrCl frmula (ml/min): Male: (140 - age) (IBW kg) (60) (Serum creatinine uml/l) (50) Female: 0.85 x male CrCl value u See Over t

Medicatin & Cnsultatin fr UA/NSTEMI Aspirin* u 160-325 mg p Clpidgrel* u 300 mg p, then 75 mg daily Metprll u 5 mg IV q 5 min prn IF HR >100 and SBP >110 and n heart failure Nitrates u Nitr 0.3-0.6 mg SL q 5 min x3 until pain free r SBP 100 Mrphine u 2-4 mg IV r subcut q 30 min prn pain Fentanyl u 50-100 mcg IV q 30 min prn pain Anticagulant (Chse ONE): Fndaparinux u 2.5 mg subcut nce daily u If cntraindicated (CrCl<30 ml/min, prsthetic heart valve r if ging t the Cath lab), use UFH Unfractinated u 60 IU/kg blus (max 4000 IU) + 12 IU/kg/hr IV infusin Heparin (UFH) (max 1000 IU/hr); target aptt: 60-80 sec Cnsult n call internist/cardilgist Triage fr cardiac u Priritized accrding t risk. Generally at higher risk, catheterizatin and therefre, the majrity shuld be cnsidered fr revascularizatin early cardiac catheterizatin, prvided the benefits f invasive assessment & revascularizatin are felt t utweigh the risks. *Administer in cmbinatin unless patient is intlerant t aspirin, r has taken previusly

TIMI Risk Scre One pint each fr: 65 years f age At least 3 risk factrs fr CAD (a) Significant crnary stensis (b) Severe anginal symptms (c) ST deviatin n presentatin Use f ASA in last 7 days Elevated serum cardiac markers (d) Ttal: Pints: Ttal number f pints = TIMI risk scre CCS risk Categry TIMI risk scre Recmmended timing f cardiac catheterizatin Lw risk u 1-2 u 5-7 days Intermediate risk u 3-4 u 3-4 days High risk u 5-7 u 24-48 hurs (a) family histry f crnary disease, hypertensin, dyslipidemia, diabetes r current smking (b) prir crnary stensis 50% (c) 2 anginal episdes in last 24 hurs (d) trpnin r creatine kinase MB u See Over t

UA/NSTEMI Wh shuld g fr cath? Risk Stratificatin and Triage fr Cardiac Catheterizatin High Risk Cath ± PCI within 24-48 hurs Hyptensin (a) r definite evidence f heart failure Recurrent ventricular arrhythmias Transient ST elevatin New ST depressin 2mm in 3 leads Recurrent r refractry ischemia despite initial therapy (b) TIMI risk scre 5-7 Intermediate Risk Cath ± PCI within 3-5 days NSTEMI withut high risk features but LVEF <40% TIMI risk scre 3-4 Lw Risk Cath ± PCI within 5-7 days NSTEMI with n high- r intermediate-risk features (c) suspected unstable angina with recurrent symptms but n ECG changes unstable angina with easily inducible (<3 METs) r widespread ischemia n nn-invasive testing, r sme ther marker f increased risk (d) TIMI risk scre 1-2 (e) Cntact Telephne Numbers: Day: Call the QEII Cardilgy Bed Manager (902) 473-6571 Evenings/Weekends/Hlidays: Page Triage Cardilgist n call (902) 473-2222 Fax: Request fr cardiac cath PCI r ther interventin (Frm # CD0720) (902) 473-2271 (a) with ther supprtive evidence f ischemia (b) definite new r dynamic ST segment changes required t justify urgent status in patients with unstable angina (nrmal trpnin level) (c) lw-risk NSTEMI patients can have invasive assessment deferred t an early utpatient setting (<2 weeks) prvided that nn-invasive testing des nt indicate easily inducible (<3METs) r widespread ischemia r sme ther marker f increased risk (d) (d) e.g. hyptensive respnse, sustained ST depressin, exercise-induced ventricular tachycardia, large territry f reversible ischemia, multiple perfusin defects, lw LVEF <40% (e) lw-risk unstable angina patients with a TIMI risk scre f 1-2 need nt necessarily underg early invasive assessment if nn-invasive testing rules ut easily inducible r widespread ischemia

Supprted by unrestricted educatinal grants frm: Cardivascular Health Nva Sctia Rm 539, Bethune Bldg. 1276 Suth Park Street, Halifax NS B3H 2Y9 902-473-7834 (T); 902-425-1752 (F) Visit ur website at www.gv.ns.ca/health/cvhns